Biobank Automation Systems Global Market Report 2025

The biobank automation systems market size has grown strongly in recent years. It will grow from $1.84 billion in 2024 to $2.03 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth observed during the historic period can be attributed to the increasing need for high-quality human biospecimens in pharmaceutical research, the rising number of academic and hospital-based biobanks, greater participation in population-based cohort and longitudinal studies, a strengthening emphasis on precision medicine and biomarker discovery using stored samples, and expanding clinical trial activity that requires centralized sample management.

The biobank automation systems market size is expected to see strong growth in the next few years. It will grow to $2.92 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth expected in the forecast period can be attributed to rising demand for centralized biobanking from pharmaceutical and biotechnology companies, expanding pipelines of cell and gene therapy products that require controlled sample storage, increasing global healthcare and life science research spending, growing outsourcing of biobanking and sample management to specialized service providers, and heightened focus on pandemic preparedness and infectious disease surveillance biobanks. Key trends anticipated for the forecast period include the development of integrated robotics-based platforms for end-to-end sample handling, the incorporation of artificial intelligence and machine learning into biobank management software, the adoption of internet of things (IoT)-enabled solutions for environmental and equipment monitoring, the implementation of cloud-based biobank information management systems with remote accessibility, and continued research and development in next-generation cryopreservation technologies for a wide range of biospecimens.

The rising prevalence of chronic diseases is expected to propel the growth of the biobank automation systems market moving forward. Chronic diseases, such as diabetes, cardiovascular diseases, cancer, and chronic respiratory disorders, are long-lasting conditions that generally progress slowly and require ongoing medical management. The increasing incidence of chronic diseases is largely attributed to population aging, with a growing number of people living into older age groups where conditions like cardiovascular disease, diabetes, and cancer are more common. Biobank automation systems help manage the growing burden of chronic diseases by enabling the reliable, large-scale storage and rapid retrieval of patient biospecimens for research, biomarker discovery, and the development of targeted therapies. For example, in February 2024, the World Health Organization (WHO) projected that global cancer incidence would exceed 35 million new cases by 2050, a 77% increase over the 20 million new cases reported in 2022. As a result, the rising prevalence of chronic diseases is driving the biobank automation systems market.

Leading companies in the biobank automation systems market are focusing on advanced innovations, such as eco-friendly cooling systems, to improve energy efficiency, reduce carbon footprints, and optimize large-scale sample storage. Eco-friendly cooling systems utilize advanced refrigeration technologies that use natural air or non-ozone-depleting refrigerants to minimize energy consumption, lower environmental impact, and support sustainable ultracold storage operations. For example, in February 2024, Azenta, Inc., a US-based life sciences company, launched the BioArc Ultra, a groundbreaking automated solution for high-density and eco-friendly ultracold sample management. BioArc Ultra enables automated, high-density ultracold sample storage and retrieval, helping biobanks maximize freezer capacity while maintaining sample integrity. The system also supports more sustainable biobanking operations through its energy-efficient design and eco-friendly refrigerants, reducing the environmental footprint of large-scale sample management. It is designed to streamline complex biorepository workflows, minimize manual handling risks, and offer secure, traceable management of critical biological samples for research and clinical applications.

In February 2023, Azenta Inc., a US-based life sciences company specializing in automated sample management and cold-chain solutions, acquired Ziath Ltd for an undisclosed amount. Through this acquisition, Azenta aims to strengthen its end-to-end sample lifecycle solutions by integrating advanced two-dimensional barcode scanning technologies that enhance accuracy, traceability, and high-throughput automation across sample registration, storage, and processing workflows for global life sciences clients. Ziath Ltd is a UK-based company specializing in advanced two-dimensional barcode readers and sample tracking technologies that support laboratory automation and biobank automation systems.

Major companies operating in the biobank automation systems market are Thermo Fisher Scientific Inc., Azenta Life Sciences, Becton Dickinson and Company, Sartorius AG, Revvity Inc., PHC Holdings Corporation, Qiagen N.V., Hamilton Company, Tecan Group Ltd., Eppendorf SE, Greiner Bio-One International GmbH, Azenta Inc., Promega Corporation, Micronic Holding B.V., BioLife Solutions Inc., Haier Biomedical Co. Ltd., LiCONiC AG, ASKION GmbH, Biologix Group Limited, LVL Technologies GmbH & Co. KG

North America was the largest region in the biobank automation systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biobank automation systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biobank automation systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The biobank automation systems market research report is one of a series of new reports that provides biobank automation systems market statistics, including biobank automation systems industry global market size, regional shares, competitors with a biobank automation systems market share, detailed biobank automation systems market segments, market trends and opportunities, and any further data you may need to thrive in the biobank automation systems industry. This biobank automation systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biobank automation systems refer to advanced automated technologies, robotics, and digital tools developed to streamline the collection, processing, tracking, storage, and retrieval of biological samples with superior accuracy, efficiency, and security. These systems reduce manual involvement, limit errors, improve sample traceability, and enable large-scale biorepository operations through integrated software, automated storage, and high-throughput workflows.

The primary product categories that make up biobank automation systems include automated storage systems, automated sample preparation systems, automated liquid handling systems, and others. Automated storage systems refer to highly engineered, temperature-controlled robotic platforms designed to store, preserve, track, and retrieve biological samples with precision and minimal manual interaction, ensuring consistent sample integrity across extensive collections. These systems are applied in key areas such as drug discovery, regenerative medicine, biobanking, and others, and are utilized by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, and other organizations.

The biobank automation systems market consists of revenues earned by entities by providing services such as system installation and validation, biobank workflow design and optimization, integration with laboratory information management systems (LIMS), preventive maintenance and equipment calibration, and training and technical support for automated biobanking operations. The market value includes the value of related goods sold by the service provider or included within the service offering. The biobank automation systems market also includes sales of automated sample storage systems, robotic liquid-handling platforms, automated tube and plate handling systems, barcode labeling and tracking solutions, and biobank sample management software. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.